Roflumilast 0.05% (Zoryve), a topical phosphodiesterase-4 inhibitor, is currently approved for treating mild-to-moderate AD in children aged 2 years or older; it was approved for ...
WESTLAKE VILLAGE, Calif. and ORLANDO, Fla., March 07, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing ...
DENVER – Topical roflumilast (Zoryve) cream 0.05% showed favorable efficacy and safety in children 3 months to up to 2 years of age with mild-to-moderate atopic dermatitis, according to new data ...
If you’re a person of color, finding the right treatment for atopic dermatitis, a common form of eczema, can be challenging. Even though the disease is more prevalent in Black Americans than white ...
FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase ...
In the INTEGUMENT-INFANT trial, 34.4% of patients achieved vIGA-AD success and 58.3% reached EASI-75 at week 4.
Itchy scalps are common and can happen to anyone, says Annie Gonzalez, MD, a dermatologist with Riverchase Dermatology. There are many different causes for an itchy scalp, and while it may be ...
Data from the INTEGUMENT trials demonstrates that ZORYVE cream 0.15% has a favorable safety profile and high tolerability, even among patients with prior inadequate responses to traditional treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results